TiGenix: Transparency notification pursuant to Article 14 of the Law of May 2, 2007
June 22 2018 - 4:01PM
REGULATED
INFORMATIONPRESS RELEASE
Transparency notification pursuant to Article
14 of the Law of May 2, 2007
Leuven (Belgium) - June 22, 2018, 22:00h
CET - TiGenix NV (Euronext Brussels and Nasdaq: TIG; "TiGenix")
announced today that it received a transparency notification
pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding
the publication of major holdings in issuers whose securities are
admitted to trading on a regulated market and including various
provisions.
Summary of the notification
On June 19, 2018, TiGenix received a
transparency notification from Philippe ODDO, following the
disposal of voting securities or voting rights on June 7, 2018,
after which Philippe ODDO (through its controlled entities ODDO BHF
ASSET MANAGEMENT SAS, ODD BHF SCA and Financière IDAT SAS) downward
crossed the lowest threshold (3%) of total voting rights of
TiGenix.
Content of the notification
Date of the notification: June 8, 2018.
Reason of the notification: acquisition or
disposal of voting securities or voting rights / downward crossing
of the lowest threshold.
Person subject to the notification requirement:
Philippe ODDO (with address at 12 Bld de la Madeleine 75 009 Paris,
France), who is a parent undertaking/controlling person.
Date on which the threshold was crossed: June 7,
2018.
Threshold that was crossed: 3%.
Denominator: 296,067,856.
Details of the notification: no details are
required when crossing the lowest threshold.
Chain of controlled undertakings through which
the holding is effectively held: ODDO BHF ASSET MANAGEMENT SAS is
100% held by ODDO BHF SCA but is independent and the notification
relates to positions held by funds managed by them. Philippe ODDO
has the control via Financière IDAT SAS (full ownership of 50.0004%
and usufruct of 49.9996%), which holds directly and indirectly
56.04% of ODDO BHF SCA, which holds 100% of ODDO BHF ASSET
MANAGEMENT SAS.
Additional information: ODDO et CIE changed its
corporate name to ODDO BHF SCA and ODDO MERITEN ASSET MANAGEMENT
SAS changed its corporate name to ODDO BHF ASSET MANAGEMENT
SAS.
This press release and the above-mentioned transparency
notification can be consulted on our website:
- press release:
http://tigenix.com/news-media/press-releases
- notifications:
http://tigenix.com/investors/share-information/shareholder-overview
For more information:
TiGenixClaudia JiménezSenior Director Investor
Relations and CommunicationsTel: +34918049264
Claudia.jimenez@tigenix.com
About TiGenix
TiGenix NV (Euronext Brussels and NASDAQ: TIG)
is an advanced biopharmaceutical company developing novel therapies
for serious medical conditions by exploiting the anti-inflammatory
properties of allogeneic, or donor-derived, stem cells.
TiGenix lead product, Alofisel
(darvadstrocel), previously Cx601, received European Commission
(EC) approval for the treatment of complex perianal fistulas in
adult patients with non-active/mildly active luminal Crohn's
disease, when fistulas have shown an inadequate response to at
least one conventional or biologic therapy. A global Phase III
trial intended to support a future U.S. Biologic License
Application (BLA) started in 2017. TiGenix has entered into a
licensing agreement with Takeda, a global pharmaceutical company
active in gastroenterology, under which Takeda acquired the
exclusive right to develop and commercialize Alofisel for complex
perianal fistulas outside the U.S. TiGenix' second adipose-derived
product, Cx611, is undergoing a Phase I/II trial in severe sepsis -
a major cause of mortality in the developed world. TiGenix is
headquartered in Leuven (Belgium) and has operations in Madrid
(Spain) and Cambridge, MA (USA). For more information, please visit
http://www.tigenix.com.
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jul 2023 to Jul 2024